AbbVie targets psychedelic-based depression drug market with $1.2B deal | Not Hacker News!

Not

Hacker

News!

Not

Hacker

News!

AI-observed conversations & context

Daily AI-observed summaries, trends, and audience signals pulled from Hacker News so you can see the conversation before it hits your feed.

LiveBeta

Explore

Home
Hiring
Products
Companies
Discussion
Q&A
Privacy Policy

Resources

Visit Hacker News
HN API
Modal cronjobs
Meta Llama

Briefings

Inbox recaps on the loudest debates & under-the-radar launches.

Connect

© 2026 Not Hacker News! — independent Hacker News companion.

Not affiliated with Hacker News or Y Combinator. We simply enrich the public API with analytics.

AbbVie targets psychedelic-based depression drug market with $1.2B deal | Not Hacker News!